Berman David M 4
4 · Immunocore Holdings plc · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Berman David M
HEAD OF R&D
Transactions
- Exercise/Conversion
Ordinary Shares
2025-11-26$17.46/sh+69,404$1,211,794→ 69,404 total - Sale
Ordinary Shares
2025-11-26$40.12/sh−69,404$2,784,488→ 0 total - Exercise/Conversion
Ordinary Shares
2025-11-28$17.46/sh+5,521$96,397→ 5,521 total - Sale
Ordinary Shares
2025-11-28$40.09/sh−5,521$221,337→ 0 total - Exercise/Conversion
Employee Share Option (Right to Buy)
2025-11-26−69,404→ 49,266 totalExercise: $17.46Exp: 2028-09-12→ Ordinary Shares (69,404 underlying) - Exercise/Conversion
Employee Share Option (Right to Buy)
2025-11-28−5,521→ 43,745 totalExercise: $17.46Exp: 2028-09-12→ Ordinary Shares (5,521 underlying)
Footnotes (4)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Immediately exercisable.